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Abstract
The objective of present study was to evaluate pharmacokinetic parameters of dibudipine 
Phytosolve after oral administration in rats. The solubility test was carried out to select 
suitable oily solvent for dibudipine. Phytosolve formulation was prepared with a medium 
chain triglyceride (MCT) oil (20%), soybean phospholipids (5%) and a 70% fructose solution 
(75%). The effect of polyol content on the mean globule size of Phytosolve formulation was 
studied. The optimized formulation was evaluated for robustness toward dilution, transparency, 
droplet size, zeta potential and transmission electron microscopic analysis. The Phytosolve of 
dibudipine with an average droplet size of 142.3 ± 4.3 nm and surface charge -18.36 ± 0.37 
mv was administered orally to rats. The average relative bioavalabilities of dibudipine in the 
plasma with Phytosolve were 170.4% and 211.2% as compared to the oily solution and aqueous 
suspension respectively. So this formulation could be offered as a useful technique to improve 
the oral delivery of the poorly water soluble drugs such as dibudipine.
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Introduction
Dibudipine (bis-t-butyl, -1, 4-dihydro-2, 
6-dimethyl-4 -(3-nitrophenyl)-3, 5-pyridine 
dicarboxylate) is a new calcium channel 
blocker which synthesized by Mahmoudian 
et al. in 1997 (1). It is a potent vasodilator 
with antihypertensive activity (2). Dibudipine 
has longer half-life (2.5 h) than other 
dihydropyridine (DHP) derivatives such 
as nitrendipine, nicardipine, felodipine, 
nislodipine and nifedipine (3). 
However pharmacokinetic studies have 
indicated very low oral bioavailability and 
high inter and intra subject variation in plasma 
concentration of dibudipine (4). It is likely due 
to low water solubility and high first pass effect 
the same as other DHPs such as lacidipine (5) 
and nitrendipine (6). 
In order to enhance clinical efficacy of this 
molecule, it is important to develop a new 
formulation to overcome these problems. In recent 
years lipid-based formulations have attracted 
researcher’s attention to themselves (7-8). Many 
studies have shown that these formulations could 
improve the oral bioavailability and plasma 
concentration profile of drugs with low water 
solubility (9). 
Phytosolve is a novel solubilizing technique 
which introduced by Wajda R. in 2003. In this 
technique phospholipids, dispersed in highly 
concentrated aqueous solution of polyol or 
carbohydrate, are able to solubilize large 
quantities of lipids, steroids, terpenes and 
polar lipids(10). The present study aimed at 
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Characterization of formulation
Measurement of size and zeta potential
The mean particle size, poly dispersity 
index and zeta potential of the Phytosolve 
formulation were measured using photon 
correlation spectroscopy instrument, zetasizer 
Nano (Malvern, UK) at 25 °C. The formulation 
was diluted with distilled water (1:100) to avoid 
particle interaction during measurement.
Physical robustness to dilution
The formulations were diluted 50, 100, 500 
and 1000 times with double distilled water. 
The diluted emulsion were evaluated for any 
physical changes such as precipitation or phase 
separation after 24 h, one week and one month 
storage in 4 °C.
Percentage transmittance
Phytosolve formulations were diluted 200 
times with distilled water and %Transmittance was 
measured using UV-Visible spectrophotometer 
(Pharmacia Biotech, UK) at 650 nm against 
distilled water as blank. The stability of different 
Phytosolve formulations (DPF, DPG, DPS) were 
assessed through transmittance measurement 30 
minute after preparation and 7 days later.
Transmission electron microscopy
A drop of diluted formulation were deposited 
on a 200 mesh holey film grid and stained with 
uranyl acetate after drying. The samples were 
observed with LEO 906 transmission electron 
microscope (ZEISS, Germany).
Pharmacokinetic study
Male Wistar rate weighing 250-300 mg 
were obtained from the Razi institute (Karaj-
Iran). The protocol of animal experimental 
study was approved by ethics committee of the 
Tehran University of Medical Sciences. The 
animals were kept in standard condition (25 
± 2° C and 55 ± 5% humidity). They fasted 
overnight with free access to water before drug 
administration. The Phytosolve and control 
formulations (oily solution, suspension) were 
administered orally (10 mg/Kg) with a gavage 
needle. The dibudipine suspension was prepared 
with hydroxymethylcellulose as suspending 
agent in water. The blood samples (500 μL) 
developing an optimal Phytosolve of dibudipine 
and evaluating its pharmacokinetic potential.
Experimental
Dibudipine and mebudipine were purchased 
from Pars Biopharmacy Research Co. 
(Tehran, Iran). Medium chain triglyceride 
(MCT), soybean phosphatidylcholine (Lipoid 
S75) kindly provided by Lipoid GmbH 
(Ludwigshafen, Germany). HPLC grade 
acetonitrile, methanol and dichloromethane 
were obtained from Merck (Darmstadt, 
Germany). Double distilled water was obtained 
through a Milli-Q system (Millipore, USA). 
The vegetable oils were provided by Barij 
Essence Co. (Kashan, Iran).
Solubility study 
The solubility of dibudipine in different 
oils including MCT, Ethyl oleate, Thistle oil, 
Olive oil, Almond oil, Walnut oil, Flax seed oil 
and Mineral oil was determined by saturation 
solubility technique (11). An excess amount of 
the dibudipine added to small volume (1 mL) 
of the solvent and vortexed for 10 min. After 
equilibration by shaking at room temperature 
for 48 h, the mixture was centrifuged at 
3000rpm for 20 min. The supernatant was 
withdrawn and filtered through a 0.2 μm syringe 
filter then analyzed by high performance liquid 
chromatography (HPLC).
Preparation of dibudipine phytosolve
For preparation of Phytosolve formulation, 
20 mg of dibudipine was dissolved in 2 g of 
MCT oil. 0.5 g of phospholipid (Lipoid S75) was 
dispersed in the 7.5 g of polyol phase at room 
temperature and homogenized using an Ultra-
Turax homogenizer (IKA T10B, Germany). 
The oily phase (MCT plus dibudipine) was 
added slowly to the phospholipid-polyol phase 
and mixed well. Final mixture was sonicated 
with a probe sonicator (Hielscher, Germany) 
with a 70% amplitude and cycle 0.6 for 10 min 
to decrease particle size in emulsion. Different 
Phytosolve formulations were prepared with 
various polyol phases such as glycerol, a 70% 
fructose solution or a 70% sucrose solution to 
achieve an optimum formulation.  
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were collected via a catheter which implanted 2 
days before the experiment in the jugular vein 
according to Thrivikraman reported protocol 
(12) in heparinized tube at 0, 10, 20, 30, 60, 90, 
120, 240 and 360 min after orally administration. 
The plasma was separated by centrifugation at 
5000 rpm for 20 min and stored at -20 ͦ C until 
analysis with HPLC.
Analysis of dibudipine concentration 
A reverse phase HPLC system containing a 
600 pump, a UV-vis detector and manual injector 
(Youngling, Korea), software (Autochro-2000) 
and a tracer excel ODS-A analytical column 
(4.6*250 mm, 5 um) was used to assay the 
plasma concentration of dibudipine. The mobile 
phase was methanol:acetonitrile:water (75:5:25) 
with flow rate 1 mL/min. The UV detector was 
adjusted on 238 nm for analysis.
Plasma sample preparation
Mebudipine was used as internal standard 
and 10 μL (4 μg/mL) of it was added to 200 μL 
of the plasma sample. There were mixed using 
a vortex mixer and 200 μL of NaOH (1 N) was 
added to them. After mixing for 1 min, 2 mL 
of dichloromethane was added and vortexed 
vigorously for 5 min and centrifuged at 5000 rpm 
for 25 min. The organic layer was transferred 
to a clean tube and evaporated at 40 °C under 
nitrogen flow. The residue was reconstituted in 
100 μL of the mobile phase and the solution (20 
μL) was injected on to the HPLC for analysis.
 The calibration curve for linearity was 
plotted using five concentrations (10, 50, 100, 
500 and 1000 ng/mL) of dibudipine in blank 
plasma. The recovery percentage of dibudipine 
was determined by comparing the peak area of 
the extracted dibudipine from the plasma with 
the peak area of obtained by the direct injection 
of a pure standard dibudipine in mobile phase 
at three different concentrations (100, 500 and 
1000 ng/mL).
The accuracy and precision of method and 
interday, intraday analysis variability were 
determined over the four concentrations (10, 
100, 500 and 1000 ng/mL) in the blank plasma. 
Various pharmacokinetic parameters 
(Cmax, Tmax, AUC and T½) were calculated 
for dibudipine Phytosolve, oily solution and 
suspension. The percent relative bioavailability 
(%F) of Phytosolve to reference formulations 
(suspension and oily solution) was calculated as 
bellow:
 
%F = (AUC0-∞ product/AUC0-∞ reference) ×100 
The maximum concentration (Cmax) and the 
time needed to reach the maximum concentration 
(Tmax) values were obtained directly from the 
concentration versus time curve.
The area under the plasma drug concentration-
time curve from 0 to 6 h (AUC0-6) was calculated 
through the trapezoidal method. The area under 
the plasma drug concentration-time curve from 0 
to infinity (AUC0-∞) was calculated via the sum 
of the areas obtained by the trapezoidal method 
(AUC0-6) and residual area (AUC6-∞). The 
residual area and T½ were obtained according to 
following equations (13).
AUCt-∞ = Ct/ke
 T½ = ln2/ke
Statistical analysis
All data are reported as mean ± S.D. Statistical 
comparisons were made using one way analysis 
of variance (ANOVA) followed by Tukey post 
hoc test at a level of significance of P < 0.05 
using SPSS software (version 14).
Results and Discussion
Solubility study
To find out an appropriate oily phase in 
Phytosolve formulation, the solubility of 
dibudipine in various oils was tested. The 
solubility of dibudipine was found to be higher 
in MCT than other oils (Figure 1) so this oil was 
selected as the solvent. 
In the present study the effect of a new 
lipid-based formulation (Phytosolve) on 
pharmacokinetic parameters of dibudipine 
after oral administration in rats was evaluated. 
Dibudipine belongs to 1, 4- dihydropyridines 
class and has low water solubility. The solubility 
of dibudipine in water is 0.00043 mg/mL. In 
order to select suitable oil with good solubilizing 
capacity for dibudipine, the solubility study was 
Keyhanfar F et al. / IJPR (2014), 13 (4): 1149-1156
1152
done. The results have shown MCT is better 
solvent respect to the other oils. Previous studies 
indicated MCTs were used in many formulations 
due to high fluidity, good solubility properties 
and emulsification ability (14), promoting 
bioavailability and lack of pharmacological 
action (15).
Selection of polyol phase
The polyol phase is another component in the 
Phytosolve formulations. It decreases polarity of 
continuous phase and interfacial tension (16) and 
facilitates microemulsification of formulations 
(17). In order to evaluate the effect of polyol phase 
on the particle sizes of formulations, different 
formulations were analyzed using zetasizer. The 
results (Table 1) have shown the kind of polyol 
has not any significant effect on the particle size 
and zeta potential of formulations. 
The percentage transmittance of the 
Phytosolve formulations (DPF, DPG, DPS) 
is indicated in Table 2. It can be seen from the 
table that the formulation DPF shows a very 
low difference in transmittance during 7 days as 
compared to other formulations. A lower value 
of transmittance differenc in formulation DPF 
can indicate the stability of this formulation.
Characterization of selected Phytosolve 
formulation
The main property of this formulation is the 
use of natural emulsifiers. The ionic and nonionic 
surfactants with short chain alcohol or amine 
cosurfactant were used in many formulations 
to form stable microemulsions. However the 
high toxicity of these surfactants limited their 
pharmaceutical usage and biocompatible 
zwitterionic naturally obtained surfactant such 
Figure1. Solubility of dibudipine in various oils; data expressed as the mean ± S.D (n=3).
Code Percentage w/w of different components in formulation Mean droplet size  ± S.D. (nm) PDI±S.D.
Mean zeta potential ± 
S.D.(mv)
Oil(20%) Polyol(75%) Phospholipid(5%)
DPF MCT Fructose Lipoid S75 142.3 ± 4.3 0.12 ± 0.02 -18.36 ± 0.37
DPG MCT Glycerol Lipoid S75 147.3 ± 6.1 0.12 ± 0.01 -18.29 ± 0.16
DPS MCT Sucrose Lipoid S75 148.5 ± 10.9 0.11 ± 0.02 -18.49 ± 0.10
Table 1. Composition, mean droplet size, polydispersity index and zeta potential of different Phytosolve formulations.
PDI indicates polydispersity index. 
DPF, DPG and DPS: dibudipine Phytosolve formulation which contained fructose solution, glycerol and sucrose solution as polyol phase 
respectively.
Dibudipine was dissolved in MCT (10 mg/g) in all the formulation (DPF, DPG, DPS). 
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Phytosolve Code %Trancmittance after 30 min %Transmittance after 7 days Transmittance difference
DPF 69.7 ± 7.6 65.4 ± 9.2 4.3
DPS 61.0 ± 9.0 69.3 ± 10.0 -8.3
DPG 58.6 ± 9.5 50.3 ± 10.5 8.3
Data expressed as the mean ± S.D (n=3).
DPF, DPS and DPG: dibudipine Phytosolve formulation which contained fructose solution, sucrose solution and glycerol as polyol phase 
respectively.
Table 2. The percent transmittance of dibudipine Phytosolve formulations at 630 nm.
as lecithin were replaced with them in the new 
formulations (18).
The Phytosolve formulation containing 
fructose (DPF) which indicated smaller particle 
size and lower change in transmittance during 
storage was selected for the pharmacokinetic 
experiments. The selected formulation (DFP) 
was exposed to different fold of dilution (50, 
100, 500 and 1000 times) with double distilled 
water. The results (no sign of separation and 
precipitation) demonstrated this formulation 
was able to mix with water in any ratio. The 
Phytosolve formulation was robust to dilution so 
it is expected that after dilution in Gastrointestinal 
(GI) fluid, dibudipine precipitation will not be 
occurred. 
 On the other hand the formulation had small 
particle size (142.3 ± 4.3 nm) and poly dispersity 
index (0.12 ± 0.02) which reflects the uniformity 
of particle diameter. In order to obtain small 
particle size, high energy input was needed. A 
probe sonicator was used in this study instead of 
high pressure homogenizer which used before. 
So the desired particle size (30-60 nm) was not 
achieved (10). 
The zeta potential measurement is used to 
identify the surface charge of droplets. The zeta 
potential of Phytosolve was -18.36 ± 0.37 mv. 
The percentage transmittance of the optimized 
formulations was 69.7 ± 7.6. As shown in Figure 
3, the morphology of droplets was spherical and 
their size was similar to the results obtained 
using zetasizer.
HPLC analysis
The extraction of dibudipine from the 
plasma samples was carried out using a 
liquid-liquid extraction procedure with three 
different solvents: ethyl acetate, ethyl ether 
and dichloromethane. Extraction recovery was 
higher with dichloromethane when compared 
with other organic solvents hence it was 
used as extraction solvent. Representative 
chromatograms of the blank plasma, a plasma 
spiked with 10 ng/mL (LLOQ) of dibudipine and 
400 ng/mL of internal standard (mebudipine) 
Figure 2. Transmission electron micrographs of the Dibudipine-containing Phytosolve. The scale bar represents a distance of 500 nm. 
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and a plasma after oral administration of 
dibudipine are presented in Figure 3. No 
interfering peaks from endogenous compounds 
are observed at the retention times of analytes. 
Retention time of dibudipine was 22 min and 
for internal standard was 11.9 min.
The assay exhibited good linearity (r2 =0.9954) 
over the range of 10-1000 ng/mL for dibudipine. 
The lower limit of quantification was 10 ng/mL 
which is acceptable for pharmacokinetic studies. 
The coefficient of variation and error were 
less than 10% for all of intraday and interday 
validation (Table 3). The recovery of dibudipine 
was found to be over 80% indicating the ability 
Figure 3. Overlay chromatograms of (A) blank rat plasma, (B) rat plasma spiked with dibudipine (LLOQ) and IS (400 ng/mL) and (C) 
rat plasma sample after oral administration of 10 mg/Kg dibudipine .
Sample concentration (ng/mL) 10 (LLOQ)a 100 (low) 500 (Medium) 1000 (High)
Intra-day(n=5)
Mean ± S.D. 9.2 ± 0.7 91.4 ± 4.1 450.0 ± 18.7 940.0 ± 41.8
CV (%)b 8.1 4.5 4.15 4.4
Error (%)c -7.8 -7.6 -10.0 -6.0
Inter-day(n=5)
Mean ± S.D. 9.1 ± 0.3 90.8 ± 2.9   502.0 ± 37.0 920.0 ± 25.5
CV (%) 3.8 3.2    7.3 2.7
Error (%) -9.0 -9.2    0.4 -8.0
Table 3. The precision and accuracy of dibudipine determination in rat plasma.
     a LLOQ: lower limit of quantification
     b Precision (at each concentration) was expressed as CV% = (SD/ mean measured concentration) × 100
     c Accuracy (at each concentration) was expressed as the Error%, which was calculated by dividing 
      The measured concentration minus the expected concentration to the expected concentration × 100.
of dichloromethane in extraction of the drug 
from plasma.
Pharmacokinetic study
 The plasma concentration-time profiles 
of dibudipine after oral administration of 
Phytosolve, oily solution and suspension are 
illustrated in Figure 4. The pharmacokinetic 
parameters of dibudipine after oral administration 
of various formulations are summarized in 
Table 4. The Cmax, AUC0-6 h and AUC0-∞ values 
of dibudipine Phytosolve were significantly 
(P < 0.001) higher than those obtained with 
oily solution and suspension but the Tmax 
was not significantly different between three 
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Figure 4. Drug-concentration time profiles of various dibudipine (DB) formulations after oral administration to rats. (n =6, 
dose=10 mg/Kg).
formulations. Dibudipine Phytosolve provided 
mean relative bioavailabilities of 170.4% and 
211.2% as compared to dibudipine oily solution 
and suspension respectively.
The in-vivo study has shown plasma 
concentration time profile of dibudipine 
Phytosolve represented greater improvement of 
dibudipine bioavailability than oily solution and 
suspension. The previous study was indicated 
fivefold increase in bioavailability of Co Q10 
and 10-fold in the case of vitamin E after 
administration of Phytosolve formulation in 
healthy volunteers (19). It was mentioned that 
phospholipids can act as a sorption promoter (19). 
Another study also have reported phospholipids 
and particularly, phosphatidylcholine can 
enhance lymphatic transport of halofantrine (20). 
Furthermore phospholipids can protect drug 
from decomposition by enzymes and bacterial 
destruction in the GI tract (21). The particle 
size plays a dominant role in the absorption 
of drugs in the GI tract. A Phytosolve particle 
size of approximately 150 nm may allow for 
efficient uptake in the intestine, particularly in 
the lymphoid sections of this tissue and therefore 
escapes from the first pass metabolism in the 
liver. The presence of phospholipids in this 
formulation besides small particle size which 
provide large interfacial area for drug absorption 
may be the possible causes of improvement 
bioavailability of dibudipine by Phytosolve.
Conclusion
The results of this study have shown 
Phytosolve formulation improved the oral 
Pharmacokinetic parameters Suspension Oily solution Phytosolve
Cmax(ng/mL) 42.2 ± 7.2 60.1 ± 6.3 99.0 ± 19.1
ab
Tmax(h) 1.00 ± 0.31 1.08 ± 0.20 1.16 ± 0.25
T1/2(h) 4.45 ±1.21 3.37 ± 1.08 3.21 ± 0.64
AUC
0→6 
(ng h/mL) 91.1 ± 9.5 126.7 ± 10.2 217.9 ± 33.4ab
AUC
0→∞  
(ng h/mL) 137.5 ± 29.5 170.4 ± 11.7 290.4 ±59.9ab
Data expressed as the mean ± S.D., n=6
a Significantly higher (p < 0.001) compared to dibudipine suspension.
b Significantly higher (p < 0.001) compared to dibudipine oily solution
Table 4. Pharmacokinetic parameters upon oral administration of various dibudipine formulations.
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